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Background and Aims: Drug-induced steatosis is a major reason for drug failure
in clinical trials and post-marketing withdrawal; and therefore, predictive biomarkers
are essential. These could be particularly relevant in non-alcoholic fatty liver disease
(NAFLD), where most patients show features of the metabolic syndrome and are
prescribed with combined chronic therapies, which can contribute to fatty liver. However,
specific biomarkers to assess the contribution of drugs to NAFLD are lacking. We aimed
to find microRNAs (miRNAs) responsive to steatotic drugs and to investigate if they could
become circulating biomarkers for drug-induced steatosis.
Methods: Human HepG2 cells were treated with drugs and changes in miRNA levels
were measured by microarray and qRT-PCR. Drug-induced fat accumulation in HepG2
was analyzed by high-content screening and enzymatic methods. miRNA biomarkers
were also analyzed in the sera of 44 biopsy-proven NAFLD patients and in 10 controls.
Results: We found a set of 10 miRNAs [miR-22-5p, -3929, -24-2-5p, -663a, -29a-
3p, -21 (5p and 3p), -27a-5p, -1260 and -202-3p] that were induced in human
HepG2 cells and secreted to the culture medium upon incubation with model steatotic
drugs (valproate, doxycycline, cyclosporin A and tamoxifen). Moreover, cell exposure
to 17 common drugs for NAFLD patients showed that some of them (e.g., irbesartan,
fenofibrate, and omeprazole) also induced these miRNAs and increased intracellular
triglycerides, particularly in combinations. Finally, we found that most of these miRNAs
(60%) were detected in human serum, and that NAFLD patients under fibrates showed
both induction of these miRNAs and a more severe steatosis grade.
Conclusion: Steatotic drugs induce a common set of hepatic miRNAs that could be
used in drug screening during preclinical development. Moreover, most of these miRNAs
are serum circulating biomarkers that could become useful in the diagnosis of iatrogenic
steatosis.
Keywords: drug-induced steatosis, predictive biomarker, microRNA, metabolic syndrome drug, hepatosteatosis,
non-alcoholic fatty liver disease
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INTRODUCTION
Drug-induced liver injury is the major reason for drug failure
in clinical trials and for the withdrawal of commercialized drugs
(Giacomini et al., 2007). Moreover, DILI is a primary cause of
acute liver failure, as it makes up to half of all acute liver failures
in the clinic (Larrey and Pageaux, 2005). DILI can arise by diverse
mechanisms and result in various clinical manifestations such as
hepatocellular lesions, necrosis, fibrosis, cholestasis, steatosis, and
phospholipidosis. Steatosis is triggered by a plethora of drugs in
current use and refers to the impairment of normal synthesis and
elimination of TG, leading to an abnormal retention of lipids
within hepatocytes (Amacher and Chalasani, 2014). Among the
drugs causing steatosis we found tetracyclines, VALP, AMIO,
TAMO and CYCA (Donato and Gomez-Lechon, 2012; Amacher
and Chalasani, 2014).
Drug-induced steatosis has the potential to cause or contribute
to NAFLD, a leading cause of liver disease in developed countries,
where it affects one-third of adults and an increasing number
of children. The disease begins with an abnormal accumulation
of TG in the liver, which in some individuals triggers
NASH, characterized by hepatocellular injury, inflammation,
and even fibrosis. NASH, in turn, can progress to cirrhosis
and hepatocellular carcinoma (Farrell and Larter, 2006; Cohen
et al., 2011). It is estimated that only a small number of
NASH cases (∼2%) are directly induced by marketed drugs
(Grieco et al., 2005). However, many other drugs may exacerbate
or precipitate fatty liver or NASH in the presence of other
risk factors (Ramachandran and Kakar, 2009). This could be
particularly relevant in NAFLD patients with MS-associated risk
factors, which are exposed to a large daily number of drugs for
hypertension, diabetes, dyslipidemias, etc. However, the potential
contribution of these drugs to fatty liver or NAFLD progression
has never been investigated.
Preclinical detection of adverse-drug reactions has failed
to detect about 40% of potentially hepatotoxic compounds in
humans (Peters, 2005). Therefore, the development of new
biomarker strategies and approaches is essential. Recently,
circulating miRNAs have been studied as emerging biomarkers
that promise early response and increased sensitivity (Amacher
et al., 2013). These features are particularly relevant for DILI
as conventional biomarkers, such as the serum transaminases
and bilirubin, are induced only after significant liver damage has
already occurred. Acetaminophen overdose, for instance, usually
produces no symptoms during the first 24 h after ingestion,
followed by the onset of liver failure. However, in this context,
some miRNAs (miR-122 and miR-192) showed an earlier and
Abbreviations: AMIO, amiodarone; AMIT, amitriptyline; ARBs, angiotensin II
receptor blockers; CITR, sodium citrate; CYCA, cyclosporin A; DILI, drug-
induced liver injury; DMSO, dimethyl sulfoxide; DOXY, doxycycline; FA, fatty
acids; FENO, fenofibrate; GO, gene ontology; HCS, high content screening;
IRBE, irbesartan; KETO, ketotifen; LORA, lorazepam; METF, metformin; miRNA,
microRNA; MMP, mitochondrial membrane potential; MS, metabolic syndrome;
NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis;
OMEP, omeprazole; PARO, paroxetine; PCA, principal component analysis; qRT-
PCR, quantitative real-time polymerase chain reaction; SIMV, simvastatin; TAMO,
tamoxifen; TG, triglycerides; TMRM, tetramethyl rhodamine methyl ester; VALP,
valproate.
less variable elevation in plasma than ALT (Wang et al., 2009),
which suggested that circulating miRNAs may be early robust
biomarkers for DILI.
microRNAs are small (∼22 nucleotide-long) non-protein
coding RNA species involved in post-transcriptional regulation.
In blood, miRNAs are stable because they are protected from
degradation by extra-cellular vesicles (such as exosomes), RNA
binding protein complexes (such as argonaute 2) and high-
density lipoproteins. Several studies have demonstrated that
hepatotoxic drugs alter miRNA levels in liver and blood, yet
most of these studies have focused on acetaminophen toxicity
(Wang et al., 2009; Starkey Lewis et al., 2011; Vliegenthart et al.,
2015). Results have shown that acetaminophen can alter the
level of ∼120 miRNAs (Vliegenthart et al., 2015), and that the
liver-specific miR-122 is one of the most sensitive biomarkers in
the context of acute liver injury. However, the effect of model
steatotic drugs on the hepatic human miRNA profile has not been
investigated yet.
In the present study, we aimed to characterize the impact
of steatotic drugs on the miRNome of human hepatic cells,
to find common signatures for this hepatotoxic outcome, and
to investigate if these miRNA biomarkers are also altered by
common MS-drugs in cultured cells. We also performed a
preliminary analysis in human serum to find if these new miRNA
biomarkers for steatotic drugs could have a potential application
in the diagnosis of steatotic DILI, particularly in NAFLD patients,
where the discrimination between iatrogenic and metabolic fat is
intrinsically difficult.
MATERIALS AND METHODS
Chemicals and Drugs
Chemical and drugs were purchased from Sigma (Madrid,
Spain), Selleckchem (Madrid, Spain) and Merck (Barcelona,
Spain). Steatosis-negative compounds (CITR, AMIT, and KETO),
used as controls, and model steatotic drugs (VALP, DOXY,
CYCA, AMIO, and TAMO) were chosen based on previous
bibliography (Gomez-Lechon et al., 2007; Donato and Gomez-
Lechon, 2012; Benet et al., 2014). The other chemicals used
in this study were common drugs prescribed to NAFLD
patients, among which we chose four antihypertensive (valsartan,
IRBE, hydrochlorothiazide, and amlodipine), two antidiabetic
(sitagliptin and METF), three lipid lowering drugs (FENO, SIMV,
and atorvastatin), one proton-pump inhibitor (OMEP), three
pain-killer (tramadol, paracetamol, and acetylsalicylic acid), two
anxiolytic (LORA and diazepam) and two antidepressant (PARO
and venlafaxine).
Patients and Serum Samples
This study comprised of 44 biopsy-proven NAFLD patients.
Disease severity was diagnosed according to the NASH CRN
scoring system and the stage of fibrosis. Patients with other
potential causes of liver disease (viral, autoimmune, metabolic
such as Wilson’s disease, etc.) were excluded. Additionally, 10
non-NAFLD subjects, who underwent surgery for cholelithiasis,
were included. These controls had normal liver, fasting glucose,
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cholesterol, TG and serum aminotransferase levels, and no
evidence of viral infections. Moreover, none consumed >20 g
alcohol per day. Anthropometric and analytical parameters
of patients included are described in Table 1. Venous blood
TABLE 1 | Clinical characteristics of patients studied.
NL
(n = 10)
NAFLD
(n = 32)
NAFLD + Fibrate
(n = 11)
Age (years) 38 ± 9.7 54.6 ± 10.5 54.6 ± 10.2
Sex
Male 4 (40%) 10 (31%) 2 (18%)
Female 6 (60%) 22 (69%) 9 (82%)
Diabetes (%) 0 (0%) 14 (44%) 7 (64%)
PAH (%) 0 (0%) 15 (47%) 8 (73%)
Dyslipidemia (%) 0 (0%) 17 (53%) 11 (100%)∗
Metabolic
Syndrome (%)
0 (0%) 19 (59%) 11 (100%)∗
Body mass index
(kg/m2)
25.8 ± 3.8 30.5 ± 6.1 34.6 ± 5.41
Triglycerides
(mg/dL)
102.6 ± 33.3 141.8 ± 69.3 262.5 ± 137.7∗
HDL-cholesterol
(mg/dL)
49.1 ± 12.2 51.8 ± 9.6 44.6 ± 15.4
ALT (IU/L) 23.5 ± 17.9 56.8 ± 45.2 75.4 ± 55.9
AST (IU/L) 20.8 ± 4.1 49.2 ± 33.1 60.3 ± 38.7
γ-GT (IU/L) 37.5 ± 56.6 110.2 ± 93.3 67.4 ± 32.8
Steatosis (%)
Grade 0 100%
Grade 1 41.4% 0.0%
Grade 2 27.6% 30.0%
Grade 3 31.0% 70.0%∗
NASH (%)
NAS_0–2 100% 27.6% 0.0%
NAS_3–4 31.0% 18.2%
NAS_5–8 41.4% 81.8%∗
Fibrosis (%)
Stage 0, 1, 2 100% 72.4% 45.5%
Stage 3, 4 27.6% 54.5%
BARD score > 2 0 (0%) 13 (42%) 5 (46%)
APRI score 0.5–1 0 (0%) 10 (31%) 5 (46%)
APRI score ≥ 1.5 0 (0%) 5 (16%) 3 (27%)
NAFLD score
–1.455 – 0.676
0 (0%) 10 (31%) 3 (27%)
NAFLD
score > 0.676
0 (0%) 18 (56%) 8 (73%)
Drugs (%)
ARBs 0 (0%) 6 (19%) 6 (55%)∗
Statins 0 (0%) 11 (34%) 4 (36%)
Metformin 0 (0%) 12 (38%) 5 (46%)
Omeprazol 0 (0%) 8 (25%) 4 (36%)
Anxiolytics 0 (0%) 8 (25%) 2 (18%)
Antidepressants 0 (0%) 4 (13%) 1 (9%)
Data are shown as mean ± standard deviation or as number of cases (%). NL,
normal liver; NAFLD, non-alcoholic fatty liver disease; HDL, high-density lipoprotein;
ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, gamma-
glutamyltransferase; PAH, pulmonary arterial hypertension; ARBs, angiotensin II
receptor blockers. ∗ P < 0.05 with respect to NAFLD group.
samples were collected in silicone-coated tubes and centrifuged
at 2500 × g for 10 min. Serum samples were maintained at
−80◦C. This study was carried out in accordance with the ethical
guidelines of the 1975 Declaration of Helsinki and with local and
national laws. The Human Ethics Committee of La Fe University
Hospital in Valencia approved this study (n 2013/0232), and all
participants signed an informed consent.
Culture of HepG2 Cells, Incubation with
Drugs and Cytotoxicity Assay
HepG2 cells (ATCC HB-8065) were grown in Ham’s F-
12/Leibovitz L-15 (1:1, v/v) medium (Invitrogen, Barcelona),
supplemented with 7% newborn calf serum, 2 mM L-glutamine,
5 mM glucose and 5 µg/mL plasmocin. HepG2 cells were seeded
at 700.000 cells/3.5 cm ∅ plate.
Compound stock solutions were prepared in DMSO or water
and were diluted in culture medium. HepG2 cells were exposed
to drugs or solvent for 24 h. The final concentration of DMSO
never exceeded 0.5% (v/v). Cytotoxicity was assessed by the
mitochondrial reduction of the yellow tetrazole MTT [3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide; Sigma,
Madrid] to a purple formazan, in cells exposed to serially diluted
drugs. Subcytotoxic concentrations (≤IC10) were calculated
from the concentration-effect curves.
Affymetrix GeneChip miRNA Arrays
Total RNA was purified from three independent HepG2 cultures
treated for 24 h with CYCA (25 µM) or solvent (0.05%
DMSO). miRNA expression profiles were analyzed by Affymetrix
GeneChip miRNA 3.0 Arrays. Microarray hybridization and
scanning were performed in IIS-LaFe microarrays platform
(Hospital La Fe, Valencia, Spain). Fluorescence values were
normalized with RMA algorithms (Robust Multichip Average)
and DABG (Detected Above Background). Partek Genomics
Suite was used in the statistical analysis applying the following
parameters: PCA, ANOVA, p-value filtering lists and hierarchical
clustering (HC) from normalized expression levels. Microarray
quality control assessment and data acquisition were performed
with the GeneChip R© Operating Software (GCOS, Affymetrix).
Quantification of miRNAs in Cells and
Serum
Total RNA was extracted from HepG2 cells with the miRNeasy
Mini Kit (Qiagen, Madrid, Spain) or from 300 µL of human
serum using Trizol LS reagent (Invitrogen, Barcelona, Spain)
followed by the miRNeasy Mini Kit. Prior to serum RNA
purification, we added 20 µg of RNase-free glycogen (Roche
Applied Sciences, Barcelona, Spain) as a carrier. Purified RNA
(1 µg) was reverse transcribed in two steps: polyadenylation
with 1U Poly(A) polymerase from E. coli (New England BioLabs,
Ipswich) and reverse transcription with an universal anchor
primer (Supplementary Table S1) and 200U M-MLV reverse
transcriptase (Invitrogen, Barcelona; Luo et al., 2012).
Diluted cDNA was amplified in a LightCycler 480 Instrument
(Roche Applied Science) using LightCycler 480 Probes Master
(Roche Applied Science) and the appropriate primers: a universal
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reverse primer, a specific forward primer for each miRNA
(Supplementary Table S1) and a universal TaqMan probe (Luo
et al., 2012). The concentration of miRNAs in the samples was
calculated with the 2-ddCt method. Sample to sample variations
were normalized with the geometric mean of two miRNAs: Let-7a
and miR-25, which are abundantly expressed in human cells and
serum, and show low variability. Moreover, these two miRNAs
showed the best stability scores in our datasets according with
the NormFinder algorithm (Andersen et al., 2004).
Quantification of Intracellular Lipids
The HCS imaging station ScanRˆ from Olympus was used
to analyze neutral lipid content and MMP, by using the
specific fluorescent probes BODIPY 493/503 and TMRM,
respectively (Molecular Probes, Invitrogen, Barcelona; Tolosa
et al., 2015).
Intracellular TG content was measured in the lipid residue
using a colorimetric kit after extraction of HepG2 homogenates
with a methanol-chloroform mixture (Gomez-Lechon et al.,
2007).
Data Analysis and Statistics
For microarray data analysis, PCA, ANOVA and filtering lists
by p-value and fold-change were performed with the Partek
Genomics Suite.
Heatmap and gene clustering analysis of the qRT-PCR
expression data was carried out with MeV: MultiExperiment
Viewer (Saeed et al., 2003). A statistical comparison of the drug-
induced effects was made by hierarchical clustering and PCA
using the web-based NIA Array Analysis tools (Sharov et al.,
2005).
Data are expressed as mean± SEM. The statistical significance
of the mean differences was evaluated by one-way ANOVA and
Tukey HSD post hoc test.
RESULTS
Effects of Cyclosporin A (CYCA) in the
miRNome of Human HepG2 Cells
We investigated first the effect of a model steatotic drug,
CYCA (Donato and Gomez-Lechon, 2012), on the whole
miRNome of HepG2 by using Affymetrix GeneChip R© miRNA
3.0 Arrays. Unsupervised PCA analysis showed a separation
between the DMSO and CYCA groups (Figure 1). Filtering
results by p-value (<0.05) provided a list of 79 miRNAs
with a significant differential expression in CYCA treated
HepG2 cells. Fifty-four miRNAs were induced and 25 were
repressed by CYCA (Supplementary Table S2). Among the most
significantly induced miRNAs we found miR-21, -22, -23, -
24, -27 and -29. We selected 35 miRNAs for further qRT-PCR
validation and for investigating if this set of miRNAs were
also responsive to other well-characterized steatotic drugs. The
miRNA selection was based on significant differences, high
confidence annotations and/or studies supporting a role in liver
lipid metabolism.
FIGURE 1 | Unsupervised PCA of global miRNA expression profiling
separates CYCA treated cells from control cells. HepG2 cultures were
incubated for 24 h with CYCA (25 µM CYCA) or solvent (0.05% DMSO).
miRNA expression profiles were analyzed by Affymetrix GeneChip miRNA
Arrays. PCA was performed with the Partek Genomics Suite.
Model Steatotic Drugs Have a Common
Fingerprint in the miRNA Profile of
HepG2 Cells
HepG2 cells were incubated with several steatotic and non-
steatotic drugs, or with 0.6 mM FA, a condition that causes
metabolic steatosis in cultured cells (Gomez-Lechon et al., 2007).
The heatmap clustering analysis of 35 miRNA in Figure 2 shows
that steatotic drugs have a common fingerprint in the miRNA
profile. Most of them triggered upregulation of miR-22-5p, -3929,
-24-2-5p, -663a, -29a-3p, -21 (5p and 3p), -27a-5p, -1260 and -
202-3p. More importantly, these miRNAs were not affected by
control drugs or by FA (Figure 2).
Hierarchical clustering of the different drugs/conditions based
on the 10 most upregulated miRNAs demonstrated that TAMO,
VALP, DOXY, and CYCA cluster together (Supplementary
Figure S1A). Only AMIO (both concentrations) grouped apart,
though in subclusters clearly separated from the subclusters of
non-steatotic compounds (KETO, AMIT, and CITR) and FA
(Supplementary Figure S1A). Finally, a PCA analysis based on
these 10 upregulated miRNA showed a clear separation between
steatotic and non-steatotic drugs (Supplementary Figure S1B).
Altogether, results indicate that steatotic drugs have a singular
fingerprint in the cell miRNome, which could be useful as a
predictive biosignature.
A more detailed analysis of miRNA expression levels, depicted
in Figure 3A, showed that CYCA, VALP, TAMO and DOXY
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FIGURE 2 | Heatmap clustering analysis of expression patterns of 35 miRNAs reveals that steatotic drugs have a common fingerprint. HepG2 cells
were treated with model steatotic (VALP, DOXY, CYCA, AMIO, and TAMO) and non-steatotic (DMSO, KETO, AMIT, and CITR) compounds for 24 h. Two different
non-cytotoxic concentrations (labeled H and L) were used. FA 0.6 mM (2:1 oleate:palmitate). Intracellular miRNA levels were analyzed by qRT-PCR-TaqMan assays
in 3–5 independent experiments and normalized with the mean of miR-let7a and miR-25. Heatmap and clustering was carried out with MeV: MultiExperiment Viewer.
Red asterisk denotes miRNAs upregulated by most steatotic drugs.
induced most of the predictive miRNAs (8–9 out of 10),
whereas AMIO had a significant effect in only 5–6 of these
miRNAs (Figure 3A). This indicates that, AMIO was the
most dissimilar steatosis-inducing drug. Another interesting
observation is that steatotic drugs preferentially trigger miRNA
induction. We attempted to validate several repressed miRNAs
in microarray analysis (e.g., miR-15a-5p and miR-15b-5p) but
only small negative effects were observed by qRT-PCR (20–30%
repression, Figure 3B). Regarding miR-126, we observed that
FA also downregulated this miRNA, and therefore it could not
be considered a biomarker specific for drug-induced steatosis
(Figure 3B).
Finally, none of the conditions assayed caused major
effects in miR-122, a recognized marker of acute liver
toxicity, in agreement with the subcytotoxic concentrations used
(Figure 3B).
Model Steatotic Drugs Increase the
Release of miRNAs to the Culture
Medium
The increase in intracellular miRNAs induced by steatotic drugs
could result in increased release of miRNAs to the extracellular
medium. To prove this is particularly important if these miRNAs
have to be tested as circulating biomarkers. We measured the
extracellular level of miRNAs (those in Figure 3A) after 24 h of
drug-incubation and found that only steatotic drugs caused an
increase in miRNA release (Supplementary Figure S2). The level
of extracellular miRNAs was several orders of magnitude below
the intracellular level, which did not allow a reliable analysis for
the less abundant miRNAs.
Common MS-Drugs Induce miRNA
Biomarkers for Drug-Induced Steatosis
Among the frequently prescribed drugs in NAFLD patients
we selected some antihypertensive, antidiabetic, lipid
lowering, proton-pump inhibitor, pain-killer, anxiolytic,
and antidepressant drugs, as specified in Section “Materials and
Methods.” Subcytotoxic concentrations were determined from
viability dose-response curves (see e.g., Supplementary Figure
S3A and Table 2). Moreover, selected concentrations were close
or below 200-fold the therapeutic peak plasma concentration
(Cmax), which is considered a relevant dosing limit for acute drug
exposure and a reasonable threshold to assess potential clinical
significance (Table 2).
Many of these drugs (60%) did not have a significant effect in
the miRNA biomarkers. However, we found that SIMV, METF,
PARO, and particularly, IRBE, FENO, OMEP and LORA were
able to significantly induce many of the miRNAs associated with
drug-induced steatosis that we identified previously (Figure 4A).
Most of the NAFLD patients are prescribed with combined
therapies and consequently we investigated the effect of some
drug combinations on the miRNA profile. We found that
combinations including FENO, IRBE, OMEP, LORA or METF
induced all the miRNA assayed (Figure 4B). We also confirmed
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FIGURE 3 | Continued
that drug combinations did not decrease cell viability by MTT
assays (see e.g., Supplementary Figure S3B).
Our results show that some commonly prescribed drugs
for NAFLD patients induce the same miRNA biomarkers as
model steatotic drugs, and therefore, they could also induce or
potentiate fatty liver in NAFLD patients.
Common MS-Drugs Induce Lipid
Accumulation in Cultured HepG2 Cells
We investigated whether MS-drugs, besides inducing biomarker
miRNAs were also able to induce fat accumulation in
cultured human hepatic cells. HCS analysis demonstrated that
BODIPY 493/503 fluorescence (neutral lipid content) increased
moderately when cells were incubated with FENO, IRBE,
OMEP and METF, and significantly when drugs were tested in
combination (Figures 5A,B). Hence, in these combined settings,
lipid accumulation was higher than that induced by the model
steatotic drug DOXY (Figure 5A).
The mitochondrion is a frequent target of cytotoxic drugs.
A loss in MMP can trigger energy imbalance, ROS induction,
impairment in Ca2+ homeostasis and apoptosis. However, the
drugs assayed did not affect MMP (as assessed by TMRM
fluorescence; Figure 5C), which further supports absence of overt
cytotoxicity at the selected concentrations.
Triglycerides are the major neutral lipids expected to
accumulate by steatotic drugs. However, there are other neutral
lipids (e.g., cholesteryl esters) that can also be stained by BODIPY
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FIGURE 3 | Expression level of selected miRNAs in cells treated with steatotic and non-steatotic drugs. Human HepG2 cells were incubated as explained
in the legend to Figure 2. Steatotic drugs, but no FA, preferentially trigger miRNA induction (A). miR-15 and miR-126 were repressed by steatotic drugs, but
miR-126 were also repressed by FA (B). The liver specific miR-122 did not respond to these drugs (B). Bars represent the mean ± SEM (n = 3–5). ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001, ANOVA, Tukey post hoc.
493/503. We measured TG levels enzymatically in the same
experimental conditions and found results that agree well with
neutral lipid levels. Once again, maximal TG accumulation was
observed upon drug coincubations (Figure 5D). Results indicate
that most of the neutral lipids accumulated by FENO, IRBE,
OMEP and METF are TG.
miRNA Biomarkers for Drug-Induced
Steatosis Can be Detected in Human
Serum and Are Elevated in NAFLD
Patients under Fibrate Therapy
Taken into account our findings in an in vitro cell model,
we could hypothesize that patients under combined therapies
with MS-drugs, such as fibrates (FENO), ARBs (IRBE) and
antidiabetics (METF), along with very frequent proton-pump
inhibitors (OMEP) and/or benzodiazepines (LORA) are at risk
of drug-induced steatosis. However, at present, there are not
clinical biomarkers able to discriminate between iatrogenic and
metabolic hepatosteatosis.
The newly in vitro discovered miRNAs will need future
translation and validation research to prove their usefulness
in vivo. However, as a proof-of-concept experiment, we have
analyzed these biomarkers in the sera of 44 NAFLD patients
and 10 non-NAFLD controls. Most of these NAFLD patients
(80%) were under drug therapy for MS-associated risk factors,
and only 11% of NAFLD patients did not take regular medication
(Table 1).
The first condition that miRNA biomarkers have to fulfill
is a reliable quantification in human body fluids (i.e., cycle
threshold ≤36–38); because accuracy, reproducibility and
precision markedly decrease when changes are detected at high
cycle thresholds. We found that some of the in vitro miRNA
biomarkers (e.g., miR-21-3p or miR-3929) were not present or
below reliable limits. However, six of them (miR-21-5p, -22 (5p
and 3p), -24-2-5p, -27a-5p and -29a-3p) were quantified with
confidence in human serum (data not shown).
Secondly, we tested if some MS-therapies are associated
with an altered serum miRNA profile in NAFLD patients. The
circulating levels of these biomarkers showed no concomitant
induction in patients under METF, ARBs, benzodiazepines,
or OMEP (data not shown). However, patients taken fibrates
showed a coincident increase in four of the six miRNAs (miR-
24-2-5p, miR-22 (5p and 3p) and mR-29a-3p; Figure 6).
Non-alcoholic fatty liver disease patients were categorized in
three histopathological groups according to the amount of fat
infiltration: mild steatosis or grade 1 without an inflammatory
component (G1, 6–33%), moderate steatosis or grade 2 (G2,
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TABLE 2 | Therapeutic and subcytotoxic concentrations of drugs for MS with significant effect on miRNA biomarkers for drug-induced steatosis.
Therapeutic group Drugs Therapeutic conc. Cmax (µM)∗ 200 × Cmax (µM) MTT range (µM) IC10 (µM) Selected conc. (µM)
Antihypertensive IRBE 7.7 1540 1250-10 150 150
Lipid-lowering FENO 83.1 16620 2500-0.15 >2500 2000
SIMV 0.02 4.0 500-3.9 7.5 7.5
Antidiabetic METF 7.8 1560 312-0.02 >300 300
Other OMEP 11.6 2320 5000-0.0005 500 300
LORA 0.8 160 1250-0.02 250 250
PARO 0.3 60 1250-0.001 125 20
∗O’Brien et al. (2006).
FIGURE 4 | Some common drugs for NAFLD patients induce the same miRNAs that model steatotic drugs. HepG2 cells were treated with subcytotoxic
concentrations (Table 2) of IRBE, FENO, SIMV, METF, OMEP, LORA, and PARO for 24 h. Drugs were added individually (A) or combined (B). Intracellular miRNA
levels were analyzed by qRT-PCR-TaqMan assays. Bars represent the mean ± SEM (n = 3–4). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ANOVA, Tukey post hoc.
33–66%) and severe steatosis or grade 3 (G3, >66%; Table 1).
Frequency distribution and chi-square test also indicated that
NAFLD patients under fibrate therapy have more severe steatosis
than other NAFLD patients (41% G1, 28% G2, 31% G3 in no
Fibrate vs. 0% G1, 30% G2, 70% G3 in Fibrate, p= 0.032 Pearson,
p= 0.08 likelihood-ratio).
The group of patients taking fibrates may also present
other differential factors that could influence serum miRNAs.
Comparison of clinical data in no Fibrate vs. Fibrate groups
showed that only serum TG were significantly different
(141.8 ± 69.3 mg/dL in no Fibrate vs. 262.5 ± 137.7 mg/dL in
Fibrate, p = 0.017 t-test; Table 1). Thus, the differences in serum
miRNAs could also be associated with serum TG. However, the
correlations between serum TG and miRNA-24-2-5p (RPearson
0.23, p = 0.13), miRNA-22-5p (RPearson 0.20, p = 0.20), miRNA-
22-3p (RPearson 0.29, p = 0.10) or mR-29a-3p (RPearson 0.058,
p = 0.71) were no significant, whereas another non-related
miRNA, miR-34a-5p, showed a strong association with serum TG
(RPearson 0.71, p< 0.0001).
Results indicate that NAFLD patients under fibrate therapy
have increased circulating levels of miRNA biomarkers of drug-
induced steatosis, as well as more severe fatty liver. Moreover,
these miRNAs are independent of serum TG levels.
DISCUSSION
This is the first study searching for miRNA biomarkers of
drug-induced hepatic steatosis in humans, which attempts
to analyze the contribution of common drugs to NAFLD.
Another recent study, published while this manuscript was
in preparation, searched for mechanistically linked miRNA
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FIGURE 5 | Some common drugs for NAFLD patients induce fat accumulation in cultured human hepatic cells. HepG2 cells were treated with IRBE,
METF, OMEP, and FENO as explained in the legend to Figure 4. Neutral lipid content (BODIPY 493/503) (A) and MMP (TMRM) (C) were quantified by HCS.
(B) Representative images from the HSC showing the fluorescence of BODIPY493/503 (neutral lipids; green) and Hoechst 33342 (nuclei; blue). Intracellular TG levels
were also determined in parallel cultures (D). Bars represent the mean ± SEM (n = 3–4). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ANOVA, Tukey post hoc.
biomarkers that distinguish between drug-induced steatosis and
human NAFLD (Liu et al., 2016). However, only one of the
top 10 miRNAs associated with drug-induced steatosis in that
study (i.e., miR-21) was also in the list of miRNA biomarkers
proposed here. The different methodological approaches of
both studies could explain this lack of correlation. Liu et al.
(2016) performed data mining in the open TG-GATEs (a
publically available microarray database) and obtained a list of
mRNAs, which were differentially expressed in the livers of rats
treated with drugs; and then, inferred deregulated miRNAs by
using a bioinformatics tool based on human data (miRTar).
This approach assume that human and rat miRNA-mRNA
interactions are 100% conserved and that all the transcriptomic
alterations are mediated by miRNAs. Secondly, only one of the
steatotic drugs selected by Liu et al. (2016; i.e., tetracycline) is
considered a model steatotic drug, and therefore, the conclusions
drawn in both studies are based on two very different sets of
compounds.
The pathogenesis of NAFLD and NASH is the result of
a complex interplay between host and environmental factors,
and drugs are relevant environmental factors that could well
be involved. Drug-induced fatty liver occurs in only some
individuals, particularly those exhibiting primary risk factors
(Amacher and Chalasani, 2014), and among these primary risk
factors we postulate metabolic NAFLD. In this regard, non-
alcoholic fatty liver is associated with mitochondrial dysfunction
and diminished hepatic energy production (Wei et al., 2008),
which may sensitize the liver to steatotic drugs, as many of
them also have the potential to interfere with mitochondrial
FA β-oxidation (Fromenty and Pessayre, 1997). The idea that
NAFLD can potentiate or favor drug-induced steatosis is also
supported by a recent study showing that the metabolic stress
induced by a high-calorie diet in mice potentiated VPA-induced
hepatosteatosis (Sathiya Priya et al., 2016).
One of the major drawbacks to investigate drug-induced
steatosis in NAFLD is the inherent difficulty in differentiating the
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FIGURE 6 | Several biomarker miRNAs for drug-induced steatosis are induced in parallel in the sera of NAFLD patients under fibrate therapy. The
levels of miRNA biomarkers were analyzed in the serum of 44 patients with NAFLD and 10 controls. Eleven of the NAFLD patients were taken fibrates regularly. Box
plots represent the 25th, the median (black line) and the 75th percentiles, a cross depicts the mean, whiskers indicate the 95th and 5th percentile and dots represent
outliers. ∗p < 0.05, ∗∗p < 0.01, ANOVA, Tukey post hoc.
metabolic/dietary influence and the contribution of concomitant
drugs. In the present study we have focused on miRNA as
potential biomarkers able to discriminate between these two
conditions. First, we used CYCA as a model steatotic drug
and found that nearly 80 miRNAs were significantly altered
in human HepG2 cells. CYCA is an immunosuppressive agent
with a narrow therapeutic index because of adverse effects on
different organs, including hepatotoxicity (Rezzani, 2004). CYCA
induces fat accumulation in cultured hepatocytes and HepG2
cells (Donato and Gomez-Lechon, 2012). The large effect of
CYCA on HepG2 miRNome is in agreement with a previous
study showing that 91 miRNAs were significantly affected by
20 µM CYCA in HepG2 when combining different time-points
(Van den Hof et al., 2015). However, CYCA, as many other drugs,
also activates other adverse outcome pathways (e.g., cholestasis)
and, therefore, not all the altered miRNAs may associate with
drug-induced steatosis.
To find common signatures, we compared CYCA with other
model steatotic drugs: VALP, DOXY, AMIO and TAMO. We
found that several miRNAs were induced by most of these
drugs, among them miR-21, -22, -24-2, -27a, -29a, -202, -663a,
-1260 and -3929. It is already known that several miRNAs
of this group (miR-21, -22, -24, 27a and -29a) target lipid
metabolism genes and pathways (Supplementary Table S3), but
there are no studies showing such an association with miR-
202, -663a, -1260 and -3929. We therefore, performed mRNA
target scan with all these miRNAs and looked for enriched
GO terms related with lipid metabolism. This analysis shows
that there is a significant enrichment in target genes with GO
terms such as lipid, fatty acid, triglyceride, phospholipid, and
cholesterol metabolism (biosynthesis, oxidation, transport, and
storage; Supplementary Table S3). This confirms the previously
reported roles of miR-21, -22, -24, 27a and -29a; and suggests
novel roles for miR-202, -663a, -1260 and -3929 in lipid
pathways.
The search for miRNA biomarkers was performed in human
HepG2 cells, but cancer derived cell lines may have an altered
miRNA profile and a disturbed response to drugs. However,
previous studies have compared the miRNomes of HepG2 and
hepatocytes, and found that only a 10% of miRNAs (193 out
of 1881 miRNAs in miRBase) were differentially expressed in
HepG2 (Bai et al., 2014). Within this list of deregulated miRNA
we only found one of our miRNA biomarkers: miR-21-3p, which
appears 2.8-fold upregulated in HepG2 cells. Other miRNAs with
increased expression in HepG2 cells were miR-27a-3p and miR-
29a-5p (2.6- and 2.9-fold, respectively; Bai et al., 2014), which
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are closely related to our biomarkers miR-27a-5p and miR-29a-
3p. Nevertheless, most of the miRNA biomarkers investigated
here were not classified as induced or repressed in HepG2 cells
and, therefore, seem to have a well-preserved expression in
HepG2.
Non-alcoholic fatty liver disease is strongly associated with
obesity, insulin resistance, hypertension, and dyslipidemia and
is regarded as the liver manifestation of the MS. Accordingly,
these patients are prescribed with combined therapies for these
conditions, and, therefore, are chronically exposed to a large
daily number of drugs. Chronic therapies lasting several weeks
or months, likely involving drug accumulation, are particularly
relevant for drug-induced hepatic steatosis (Amacher and
Chalasani, 2014).
We tested the possibility that MS drugs could be steatotic.
We assessed the effect of 17 different common drugs of NAFLD
patients in the miRNA profile and found that some of them
were also able to induce the miRNAs biomarkers for drug-
induced steatosis, particularly when combined. Moreover, these
drugs also induced fat accumulation in HepG2 cells. The drugs
with steatogenic potential were FENO, IRBE, METF, OMEP and
LORA, and among them FENO was particularly significant.
Fibrates, such as FENO, are PPARα agonists widely used in
clinical practice as lipid modifying agents that can improve TG
plasma levels and the atherogenic lipoprotein profile. However,
their effect on liver steatosis is controversial. Some studies have
shown that besides lowering plasma TG, fibrates also ameliorate
liver steatosis in animal models (Harano et al., 2006; Shiri-
Sverdlov et al., 2006); but these studies are in clear contrast with
others: serum TG were reduced but hepatic TG were increased in
FENO-treated mice (Yan et al., 2014); ob/ob and LDLR-double
deficient mice significantly increased the hepatic TG content
and the number and size of lipid droplets after FENO (Rull
et al., 2014); combined treatment of FENO with LXR or PPARγ
agonists exacerbated hepatic steatosis (Gao et al., 2013; Rull et al.,
2014); mice treated with FENO have even been used as a model
of fatty liver (Le et al., 2014). These studies agree with the fact
that FENO mediates induction of not only FA oxidation but
also FA synthesis and elongation (Oosterveer et al., 2009). Our
results demonstrate that both lipid accumulation and biomarker
miRNAs for drug-induced steatosis are induced in HepG2 cells
incubated with FENO, and that both the steatosis grade in
the liver and the serum miRNA biomarkers are significantly
increased in NAFLD patients under fibrate therapy. Thus, it is
tempting to speculate that the use of fibrates in patients with
established NAFLD may have adverse effects on the severity of
the liver disease. It remains to be investigated if all the fibrates act
as FENO or if some of them have no steatotic side effects, and
could be more safely prescribed for NAFLD patients.
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